Immune-mediated necrotizing myopathy typically presents with progressive symmetrical proximal muscle weakness and myalgias, although some cases can present with respiratory and esophageal muscle weakness, as seen in this reported case study.
With statins carrying a risk of myopathy, researchers are sharing the details of a case report of a patient with statin-induced necrotizing myositis, published recently in Cureus.
The patient, who had been on statins for 5 years, presented with generalized fatigue, elevated creatine kinase levels above 2000 U/L, and elevated creatinine of 1.6 mg/dL. Testing showed that a mitosis panel was negative and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody was positive.
A statin-induced necrotizing autoimmune myopathy (SINAM) diagnosis was made following further testing that showed scattered necrotic fibers with minimal perivascular inflammation. Even after discontinuing statin treatment the patient continued to experience muscle weakness and progressive dysphagia.
Based on their findings, the researchers explained, “Physicians should consider the onset of SINAM when patients treated with statins present with myalgias, proximal muscle weakness, and very high creatine phosphokinase levels even after chronic use of statins. Also, physicians should screen for antibodies against 3-hydroxy-3-methylglutaryl coenzyme Areductase and stop statin therapy immediately. Patients should be started on steroids, as the disease can progress even after discontinuation of the statins and can be debilitating if it involves respiratory muscles and esophageal muscles.”
In addition to steroids, management can include oral high-dose steroids and intravenous immunoglobulin and adjuvant therapies like methotrexate, azathioprine, and rituximab.
According to the researchers, immune-mediated necrotizing myopathy typically presents with progressive symmetrical proximal muscle weakness and myalgias, although some cases can present with respiratory and esophageal muscle weakness, as seen in the reported case study.
“Generally, SINAM is more prevalent in patients who are positive for the human leukocyte antigen-DR isotype. The type of statin used is also a factor, as lovastatin, simvastatin, and atorvastatin have more effects on muscles,” wrote the researchers. “Dose strength is another risk factor, as the higher dose of the statins is associated with a greater risk of muscle injury. As hepatic cytochrome P450 3A4 (CYP3A4) metabolizes statins, patients on other drugs that affect the metabolism of CYP3A4, like macrolides, azoles, cyclosporine, colchicine, calcium channel blockers, fibrates, and amiodarone, are more prone to SINAM.”
Reference
Ahmad A, Karam I, Baker DL. A rapidly debilitating myopathy: a rare case of statin-induced necrotizing myositis. Cureus. Published online July 10, 2021. doi:10.7759/cureus.16304
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More